Amyotrophic lateral sclerosis (ALS)

#Amyotrophic lateral sclerosis (ALS) #Motor neurone disease #Neurodegenerative disorders #Neuroscience #Nevrargenics

Promising new therapy for ALS progresses to human trials

A new treatment for the most common type of motor neurone disease (MND) could improve the neuronal health of sufferers and allow their nervous systems to improve regeneration. Ellorarxine, a novel drug compound developed by Nevrargenics, has demonstrated antioxidant and anti-inflammatory effects, which make it a… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug discovery #Neuroscience

The latest advancements driving neuroscience drug discovery research

In this webinar, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Dr Klein shares how Dewpoint applies insights into… Read More

Webinar date:
Supported by Apconix
#Webinars

Neuroscience innovation
#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

Last chance: Driving neuroscience drug discovery research

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

What are the latest advancements driving neuroscience drug discovery?

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

Webinar on driving neuroscience drug discovery research

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

The latest advancements driving neuroscience drug discovery

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

Demyelination of neuron
#Amyotrophic lateral sclerosis (ALS) #Animal models #Charity #Funding #MND #NRG Therapeutics

mPTP Inhibitors block mitochondrial dysfunction in ALS

NRG Therapeutics has been awarded a non-dilutive grant from Target ALS Foundation to support its discovery programme for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neurone disease. It is one of five recipients of the 2024 In Vivo Target Validation grants… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Dementia #epilepsy #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's

New DDW Highlights podcast: 29 July 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. There have been some interesting developments in neuroscience this week. Perhaps most note-worthy,… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Dementia #epilepsy #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's

This week in drug discovery (22-26 July) 

News round-up for 22-26 July by DDW Senior Digital Content Editor Diana Spencer. There have been some interesting developments in neuroscience this week. Perhaps most note-worthy, shingles vaccines Shingrix has been shown to reduce the risk of dementia by 17%, and TikoMed’s ALS drug caused a long-term slowing… Read More

#News

Cancer research
#Amyotrophic lateral sclerosis (ALS) #Neurology #Neuroscience #Phase II trial #TikoMed

‘Encouraging’ results for potential disease-modifying ALS drug

New clinical data have shown that TikoMed’s low molecular weight dextran sulfate compound ILB is safe and well tolerated in patients with amyotrophic lateral sclerosis (ALS). The trial was carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics… Read More

#Editor's Choice #News

Demyelination of neuron
#Amyotrophic lateral sclerosis (ALS) #Neurodegenerative disorders #Neuroscience #Partnership

New Scandinavian ALS drug research collaboration

The Division of Clinical Neuroscience at Oslo University Hospital (OUS) and the Swedish drug development company TikoMed have signed a research collaboration agreement focused on amyotrophic lateral sclerosis (ALS). TikoMed has previously completed and reported on two successful Phase IIa clinical studies in ALS, one at… Read More

#News

ALS concept
#Amyotrophic lateral sclerosis (ALS) #Biomarkers #Drug discovery #Neuroscience #Partnership

How a new partnership aims to tackle ALS

DDW Editor Reece Armstrong speaks to Alessio Travaglia, PhD, Director, Translational Science, Neuroscience, Foundation for the National Institutes of Health (FNIH) about challenges in treating amyotrophic lateral sclerosis (ALS) and why a new public-private partnership launched by the FNIH is hoping to advance new drugs and diagnostics for the disease.   RA:… Read More

#Exclusive Content

Motor neuron disease awareness day
#Amyotrophic lateral sclerosis (ALS) #Motor neuron disease #Neurodegenerative disorders

Six advances in drug discovery for MND / ALS

Ahead of Motor Neurone Disease (MND) Awareness Day on 21 June, we take a look back over the latest developments in the treatment of MND and amyotrophic lateral sclerosis (ALS). A new UK research partnership In June, UK charity LifeArc pledged £1.5 million to fund a… Read More

#News #Trending News

#Amyotrophic lateral sclerosis (ALS) #Biotechnology #Broken String Biosciences #DNA #Francis Crick Institute #Genomics

UK industry collaboration to advance ALS research 

Broken String Biosciences has entered a research collaboration with the Francis Crick Institute, focused on leveraging technology to investigate the impact of genomic instability in the development of amyotrophic lateral sclerosis (ALS).  The aim to achieve this is through the development of novel applications for Broken String’s… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Clinical trial #Clinical trials #Cystic fibrosis #Parkinson's #TB

New DDW Highlights podcast: 22 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The headline news this week all concerns clinical trials for new drugs that could… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Clinical trial #Clinical trials #Cystic fibrosis #Parkinson's #TB

This week in drug discovery (15-19 April) 

News round-up for 15-19 April by DDW Digital Content Editor Diana Spencer. The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s. Read More

#News